Filtered By:
Condition: Multiple Sclerosis
Management: National Institutes of Health (NIH)
This page shows you your search results in order of date.
Order by Relevance | Date
Total 12 results found since Jan 2013.
Differences in the choroid plexus volume and microstructure are associated with body adiposity
The choroid plexus (CP) is a cerebral structure located in the ventricles that functions in producing most of the brain’s cerebrospinal fluid (CSF) and transporting proteins and immune cells. Alterations in CP structure and function has been implicated in several pathologies including aging, multiple sclerosis, Alzheimer’s disease, and stroke. However, identification of changes in the CP remains poorly characterized in obesity, one of the main risk factors of neurodegeneration, including in the absence of frank central nervous system alterations. Our goal here was to characterize the association between obesity, measur...
Source: Frontiers in Endocrinology - October 13, 2022 Category: Endocrinology Source Type: research
NIH scientists build a cellular blueprint of multiple sclerosis lesions
Chronic lesions with inflamed rims, or "smoldering" plaques, in the brains of people with multiple sclerosis (MS) have been linked to more aggressive and disabling forms of the disease. Using brain tissue from humans, researchers at the National Institutes of Health's National Institute of Neurological Disorders and Stroke (NINDS) built a detailed cellular map of chronic MS lesions, identifying genes that play a critical role in lesion repair and revealing potential new therapeutic targets for progressive MS.
Source: World Pharma News - September 10, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
CWRU researcher secures $1.2M to develop MS diagnostic tests
(Case Western Reserve University) Case Western Reserve University researcher Farren Briggs was awarded $1.2 million over three years from the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health to identify biomarkers to improve the diagnoses of multiple sclerosis (MS), including the ability to monitor disease activity and progression.
Source: EurekAlert! - Medicine and Health - June 10, 2021 Category: International Medicine & Public Health Source Type: news
12 Innovations That Will Change Health Care and Medicine in the 2020s
Pocket-size ultrasound devices that cost 50 times less than the machines in hospitals (and connect to your phone). Virtual reality that speeds healing in rehab. Artificial intelligence that’s better than medical experts at spotting lung tumors. These are just some of the innovations now transforming medicine at a remarkable pace.
No one can predict the future, but it can at least be glimpsed in the dozen inventions and concepts below. Like the people behind them, they stand at the vanguard of health care. Neither exhaustive nor exclusive, the list is, rather, representative of the recasting of public health and medic...
Source: TIME: Health - October 25, 2019 Category: Consumer Health News Authors: TIME Staff Tags: Uncategorized HealthSummit19 technology Source Type: news
New Partnership Forms to Develop Breakthrough Neuromodulation Device
WeHealth, an e-health department of Servier Group, said it is in a partnership with Pathmaker Neurosystems, a pioneering clinical-stage bioelectronic medicine company. The two companies revealed plans to develop and commercialize the first neuromodulation technology designed to treat muscle spasticity non-invasively. The new technology will be known as the MyoRegulator device.
The new MyoRegulator PM-200 provides a non-invasive treatment option for patients suffering from muscle spasticity, a common condition found in many patients suffering from stroke, cerebral palsy, multiple sclerosis, spinal cord injury, and traumatic...
Source: MDDI - March 26, 2019 Category: Medical Devices Authors: Kristopher Sturgis Tags: Business Source Type: news
Be Aware and Beware: Chronic Fatigue Syndrome Is an Equal Opportunity Disease
Chronic Fatigue Syndrome, or CFS, is an innocuous name given to a debilitating disease. Its seriousness is better indicated by the term Myalgic Encephalomyelitis (ME), a label preferred by many of its victims. On May 17-18, the Department of Health and Human Services hosted the biannual public meeting of the Chronic Fatigue Syndrome Advisory Committee by webinar. This was a fitting time for such a meeting, as May is International ME/CFS Awareness Month.
The trigger for CFS/ME is not known. The lack of research on the disease means there is no truly effective and widely available therapy that would allow the more serious...
Source: Healthy Living - The Huffington Post - May 20, 2016 Category: Consumer Health News Source Type: news
A Survey of Functional Movement Disorders at the National Institutes of Health (P1.073)
OBJECTIVE: To better characterize the clinical presentation of functional movement disorders. BACKGROUND: Functional (psychogenic) movement disorders are receiving greater attention as valid and treatable neurologic disorders. Unfortunately, the often long list of complaints with variable presentations may hamper timely diagnosis and treatment. METHODS: We reviewed 113 charts retrospectively of patients presenting to the National Institutes of Health. Patients were referred from 44 states and the District of Columbia, with the majority presenting from the local Washington D.C. metropolitan area. Most patients were diagnose...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Ahmad, O., Maurer, C., Villegas, M. A. F., Lungu, C., Hallett, M. Tags: Movement Disorders: Miscellaneous Source Type: research
UCLA researchers provide first evidence of how obstructive sleep apnea damages the brain
Courtesy of Rajesh Kumar
Brains with obstructive sleep apnea (left) and without
UCLA researchers have reported the first evidence that obstructive sleep apnea contributes to a breakdown of the blood–brain barrier, which plays an important role in protecting brain tissue.
The discovery, reported in the Sept. 1 issue of the Journal of Neuroimaging, could lead to new approaches for treating obstructive sleep apnea, which affects an estimated 22 million American adults. The disorder causes frequent interruptions in breathing during sleep because the airways narrow or become blocked.
The blood–brain barrier limits harmful...
Source: UCLA Newsroom: Health Sciences - September 1, 2015 Category: Universities & Medical Training Source Type: news
UCLA researchers discover new gene involved in Parkinson's disease
In the past decade, scientists have identified a handful of genes connected with Parkinson's disease. Now, a team of UCLA researchers has identified another gene involved in the neurological disorder. Their finding may provide a target for drugs that could one day prevent or even cure the debilitating illness.
Parkinson's disease is the second most common neurodegenerative disorder, after Alzheimer's disease, and it has no cure. About 60,000 Americans are diagnosed with Parkinson's disease each year, and it is estimated that as many as 1 million Americans live with Parkinson's disease – more than the number of people wit...
Source: UCLA Newsroom: Health Sciences - June 9, 2014 Category: Universities & Medical Training Source Type: news
Quick magnesium treatment fails to improve stroke outcomes, but study has silver lining
In the first study of its kind, a consortium led by UCLA physicians found that giving stroke patients intravenous magnesium within an hour of the onset of symptoms does not improve stroke outcomes.
However, the 8-year trial did find that with the help of paramedics in the field, intravenous medications can frequently be administered to stroke victims within that so-called "golden hour," during which they have the best chance to survive and avoid debilitating, long-term neurological damage.
The latter finding is a "game-changer," said Dr. Jeffrey Saver, director of the UCLA Stroke Center and a professor of ...
Source: UCLA Newsroom: Health Sciences - February 13, 2014 Category: Universities & Medical Training Source Type: news
Researchers ID more pesticides linked to Parkinson's, gene that increases risk
This report provides evidence for the relevance of ALDH inhibition in Parkinson's disease pathogenesis, identifies pesticides that should be avoided to reduce the risk of developing Parkinson's disease and suggests that therapies modulating ALDH enzyme activity or otherwise eliminating toxic aldehydes should be developed and tested to potentially reduce Parkinson's disease occurrence or slow its progression, particularly for patients exposed to pesticides," the study states.
The study was funded in part by the National Institute of Environmental Health Sciences (P01ES016732, R01ES010544, 5R21ES16446-2 and U54ES0120...
Source: UCLA Newsroom: Health Sciences - February 3, 2014 Category: Universities & Medical Training Source Type: news
Pesticides and Parkinson's: UCLA researchers uncover further proof of a link
For several years, neurologists at UCLA have been building a case that a link exists between pesticides and Parkinson's disease. To date, paraquat, maneb and ziram — common chemicals sprayed in California's Central Valley and elsewhere — have been tied to increases in the disease, not only among farmworkers but in individuals who simply lived or worked near fields and likely inhaled drifting particles.
Now, UCLA researchers have discovered a link between Parkinson's and another pesticide, benomyl, whose toxicological effects still linger some 10 years after the chemical was banned by the U.S. Environment...
Source: UCLA Newsroom: Health Sciences - January 3, 2013 Category: Universities & Medical Training Source Type: news
